Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill

July 27, 2026 11:40 AM EDT News Briefing Yarrow to be­gin trad­ing as it tar­gets Graves; FDA ap­proves Ot­suka's AD­HD pill ENDPOINTS Plus news about Out­look Ther­a­peu­tics, Gos­samer Bio, Ap­n­imed and En­tera Bio. 📈 Yarrow clos­es merg­er to go pub­lic: Yarrow Bio­science is de­vel­op­ing an an­ti-TSHR an­ti­body … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER